Neoadjuvant chemoradiotherapy for clinical stageIV pancreatic cancer.

Neoadjuvant chemoradiotherapy for clinical stageIV pancreatic cancer. - Neoadjuvant chemoradiotherapy for clinical stageIV pancreatic cancer.

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000006782

Enrollment

Registered

2011-11-28

Start date

2009-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pancreatic cancer

Interventions

TS-1 60mg/m2 Gemcitabine 1000mg/m2 radiation 30Gy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Over 20 years old, clinical stageIV pancreatic cancer, resectable case

Exclusion criteria

Exclusion criteria: Under the age of 19, unresectable case

Design outcomes

Primary

Measure	Time frame
Overall survival	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026